A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naïve adults and...

Full description

Bibliographic Details
Main Authors: Alphonse Ouédraogo, Alfred B Tiono, Désiré Kargougou, Jean Baptiste Yaro, Esperance Ouédraogo, Youssouf Kaboré, David Kangoye, Edith C Bougouma, Adama Gansane, Noelie Henri, Amidou Diarra, Souleymane Sanon, Issiaka Soulama, Amadou T Konate, Nora L Watson, Valerie Brown, Jenny Hendriks, Maria Grazia Pau, Isabella Versteege, Edison Wiesken, Jerald Sadoff, Issa Nebie, Sodiomon B Sirima
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3823848?pdf=render

Internet

http://europepmc.org/articles/PMC3823848?pdf=render

Similar Items